scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1034653442 |
P356 | DOI | 10.1007/S00296-004-0571-9 |
P698 | PubMed publication ID | 15726373 |
P50 | author | Nicola Martinelli | Q42699987 |
P2093 | author name string | Paola Caramaschi | |
Alessandro Volpe | |||
Antonio Carletto | |||
Domenico Biasi | |||
Lisa Maria Bambara | |||
Sara Pieropan | |||
Elisabetta Tonolli | |||
P2860 | cites work | Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies | Q24564876 |
C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity | Q24675774 | ||
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
Review article: safety of infliximab in clinical trials | Q33793931 | ||
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials | Q33925623 | ||
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy | Q33973488 | ||
Clinical utility of the anti-CCP assay in patients with rheumatic diseases | Q35553110 | ||
Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. | Q40569388 | ||
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis | Q42631739 | ||
Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). | Q43659678 | ||
A lupus-like syndrome associated with infliximab therapy | Q44469108 | ||
Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. | Q44511565 | ||
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis | Q44541019 | ||
Citrullination of synovial proteins in murine models of rheumatoid arthritis | Q44586791 | ||
High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis | Q44661580 | ||
Infliximab-induced lupus in Crohn's disease: a case report. | Q44692619 | ||
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide | Q44791267 | ||
Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis | Q46376254 | ||
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study | Q47771380 | ||
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy | Q49031401 | ||
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity | Q56595317 | ||
Anti-TNF-alpha-induced systemic lupus syndrome | Q73046347 | ||
Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab) | Q73168489 | ||
Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies | Q73202398 | ||
Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis | Q73249154 | ||
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial | Q73775013 | ||
Etanercept-induced subacute cutaneous lupus erythematosus | Q77174829 | ||
In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL | Q77337880 | ||
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
Drug-induced systemic lupus erythematosus associated with etanercept therapy | Q77696979 | ||
Drug-induced systemic lupus erythematosus and TNF-alpha blockers | Q94077789 | ||
P433 | issue | 1 | |
P921 | main subject | rheumatoid arthritis | Q187255 |
P304 | page(s) | 58-62 | |
P577 | publication date | 2005-02-23 | |
P1433 | published in | Rheumatology International | Q15763689 |
P1476 | title | Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment | |
P478 | volume | 26 |
Q35207886 | A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis |
Q34896439 | Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study |
Q44830835 | Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis |
Q35475541 | Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis |
Q43195995 | Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis |
Q24627677 | Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies |
Q35645491 | Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis |
Q24675281 | Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review |
Q35760039 | High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis |
Q36733774 | Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris |
Q44343787 | Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. |
Q35741161 | Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies |
Q90176726 | Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D |
Q79736443 | Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis |
Q40329877 | Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis |
Q86848982 | Psoriatic arthritis |
Q37353700 | Rheumatoid factors: clinical applications |
Q83081026 | Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis |
Q47615878 | Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis |
Q37280952 | The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases |
Q35636615 | The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis |
Q27022645 | The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses |